Table 1.
Sunitinib (n = 56) | Sorafenib (n = 47) | P‐value | |
---|---|---|---|
Mean age (SD) | 60 (8.2) | 59 (9.6) | 0.73 |
Men, no. % | 39 (70%) | 37 (79%) | 0.12 |
Prior sunitinib therapy | – | 10 | |
Prior sorafenib therapy | 19 | – | |
Macrocytosis at baseline | 0 | 0 |
Sunitinib (n = 56) | Sorafenib (n = 47) | P‐value | |
---|---|---|---|
Mean age (SD) | 60 (8.2) | 59 (9.6) | 0.73 |
Men, no. % | 39 (70%) | 37 (79%) | 0.12 |
Prior sunitinib therapy | – | 10 | |
Prior sorafenib therapy | 19 | – | |
Macrocytosis at baseline | 0 | 0 |